National Institutes of Health (NIH): Intramural Research Program (IRP)’s Post

How do mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) within extracellular vesicles initiate neuroinflammation in neurodegenerative disorders? Carla Lopes, from Universidade de Coimbra, will elucidate this mechanism during her presentation at Targeting EVs 2024 in Malta on October 17-18. 🔗 Read more: https://lnkd.in/dPGU9gFg Stay tuned to explore groundbreaking EVs advancements that could reshape our understanding and treatment of neurodegenerative diseases. 🌐 Conference website: https://lnkd.in/dMm8jZjd #Neuroinflammation #EVs #Mitochondria #TargetingEVs

📰 We are thrilled to highlight that our #breakthrough in Parkinson's diagnostics was featured in Parkinson's News Today. "This discovery marks a monumental step forward in our understanding and ability to diagnose this challenging condition." wrote Margarida Maia, PhD in the article. Read the article on Parkinson's News Today here https://lnkd.in/gJsC93Dc BPGbio's ParkinsonDx is another product of our NAi Interrogative Biology Platform in identifying a biomarker for disease diagnosis. How does our platform work? Read here: https://lnkd.in/gvTXPEEf For BD inquires, email BD@bpgbio.com #ParkinsonsDisease #EarlyDetection #Biomarkers #MedicalResearch #HealthcareInnovation #BPGbio #NeurodegenerativeDiseases #PatientCare #diagnostics #AIdrugdiscovery #AIplatform

The NIA-AA Research Framework has refined our approach to Alzheimer's disease (AD), emphasizing biological markers over clinical symptoms. With this established framework, AD is now defined by detectable biomarkers in living patients. This essential shift allows for earlier identification of the disease through markers of beta-amyloid deposition, pathologic tau, and neurodegeneration, known collectively as the AT(N) framework. By targeting the biological underpinnings of AD, this methodology not only deepens our understanding but also enhances the precision of both research and treatment strategies, potentially halting the disease before symptoms significantly advance. 🧠How do you see this evolution influencing our strategies in combating AD? #AlzheimersResearch #BiologicalMarkers #HealthcareInnovation

Progress in translational research has been impeded by a lack of highly multiplexed and ultrasensitive proteomic technologies. #NULISA is addressing this challenge and changing the way we profile proteins from biofluids. Stop by our poster this week at Keystone Symposia's meeting on Neurodegenerative Diseases in Santa Fe, NM. Meet with Douglas Hinerfeld and Max Mahoney learn more! https://ow.ly/bW5O50S6rgx #KSNeurodegen24

The epigenome is a dynamic force that can change dramatically as we age. In this fascinating review paper, the authors explore how DNA methylation changes during aging and how those patterns can predict future health and lifespan. The authors also explore how changes in methylation can affect the pathophysiology of age-related and neurodegenerative conditions, such as Parkinson's disease. Read more here: https://bit.ly/3UQ7kBg #Aging #Epigenetics

This month, we are showing the work of Dominykas Veiveris. His project is about Liquid-liquid phase separation (LLPS) phenomena, during which proteins form liquid droplets, followed by amyloid aggregation. LLPS is observed in neurodegenerative disorders, cancers and certain cases is related to protein functions in the cell nucleus. Watch below as alpha-synuclein, a protein linked to Parkinson's disease, undergoes LLPS. #LLPS #Science #LifeSciencesCenter #VilniusUniversity

Quantification of α-synuclein aggregates In the development of Parkinson’s disease (PD), the changes that will lead to neurodegeneration take place in the brain long before patients show any symptoms. But without a test that can detect these changes, it’s difficult to intervene early to more effectively slow disease progression. To address this need, researchers have developed a molecular assay platform that they successfully applied to patient samples to detect and quantify single ⍺-synuclein fibrils, the pathogenic aggregates of ⍺-synuclein that are a hallmark of PD and other neurodegenerative disorders collectively known as ⍺-synucleinopathies. #ScienceMission #sciencenewshighlights https://lnkd.in/gYzjHu8b

It's Total Health Tuesday! Each week we'll be highlighting a different part of 23andMe+ Total Health, our most advanced health membership. Today we're discussing how genetic insights from DNA sequencing can impact your health. Exome sequencing can provide deeper insights into an individual's genetic makeup, identifying variations that may be linked to specific genetic disorders or conditions. 23andMe+ Total Health offers clinician-ordered exome sequencing and clinical interpretations of 100+ high impact genes. These genes are associated with 55+ health conditions that if detected early may have effective preventative measures and clinical interventions. Our 23andMe+ Total Health membership will receive reports for hereditary conditions related to cancer, cardiovascular, metabolic, kidney, neurological, and other health conditions. Learn more: https://23and.me/3VdLtUL #totalhealthtuesday

#DYK? Neurodegenerative diseases like #ALS and #MS are characterized by energy deficits in neurons that ultimately result in cell death. Our investigational nanotherapeutic #CNMAu8 restores neuronal energy by aiding mitochondrial function, driving its potential use across multiple diseases. Learn about our clinical pipeline here: https://bit.ly/3J9LcbH

The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic https://lnkd.in/giavG4wb by Ai Huey Tan, Shen Yang Lim and Anthony Lang Further readings: 1. Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies (2023) https://lnkd.in/gGwgTcK3 2. Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson's Disease from Mice to Human (2023) https://lnkd.in/gTdk3PaT 3. Microbiome and Metabolome Insights into the Role of the Gastrointestinal-Brain Axis in Parkinson's and Alzheimer's Disease: Unveiling Potential Therapeutic Targets (2022) https://lnkd.in/gANDNZT5 4. Gut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis (2019) https://lnkd.in/gBqX-TWe